Imagine trying to use a key made for a human lock to open a dog's door; it often doesn't fit and can cause damage. This project created a specialized 'key-maker' specifically for dogs to create medicines that fit their bodies perfectly. It focuses on stopping the inflammation that causes chronic gut issues in pets without triggering a negative immune reaction.
Current IBD treatments for dogs often rely on adapted human drugs, which can trigger immune responses and prove ineffective. This creates significant financial and emotional stress for pet owners and a gap in the veterinary pharmaceutical market.
A fully synthetic canine phage display platform (CAESAR) and a functional cell assay for validating antibody functionality in target tissue.
If you are a drug developer dealing with the failure of 'petized' human drugs in dogs — this project developed a fully synthetic canine phage display platform that creates species-specific antibodies. This avoids the immune responses that make adapted human therapies ineffective.
If you are a lab dealing with low affinity in canine antibody candidates — this project developed the CAESAR platform to efficiently block pro-inflammatory factors. It provides a method for de novo selection of therapeutic antibodies for various canine diseases.
If you are a clinic network dealing with the high emotional and financial distress of owners with dogs suffering from IBD — this project developed a lead candidate validated in 3D organoid models. This aims to provide a more effective, targeted treatment option for chronic gut conditions.
The project aims for a cumulative profit of 41 M in the first five years of commercialization with an ROI of 14. Based on available project data, these are the projected business targets.
The project intends to use the in vivo validated lead candidate and its data package for future out-licensing activities. Based on available project data, the goal is to license the developed substrates.
The project includes a phase for GMP production aiming for a high expressing stable cell line. Based on available project data, this is intended to support the transition to commercial manufacturing.
The project period was from 2022-05-01 to 2024-04-30. By the end of the funding period, the first half of the affinity maturation for the backup target was finished.
It replaces 'petization' (adapting human drugs) with species-specific antibodies. This prevents the immune responses that often make current adapted therapies ineffective.
The project is led by a single SME, ADIVO GMBH from Germany, representing a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as the coordinator is the sole entity responsible for both the technical development of the CAESAR platform and the subsequent out-licensing strategy.
Contact ADIVO GMBH regarding the CAESAR canine phage display platform and IBD lead candidates.
Contact us to explore licensing opportunities for the CAESAR canine antibody platform.
